PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Lucia M. Novak, MSN, ANP-BC, BC-ADM, CDTC - The Art of Medicine: Creating Treatment Regimens With GLP-1 RAs to Reduce Cardiovascular Risks in Patients With T2DM
Go online to PeerView.com/SVU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) describes shared decision-making strategies to individualize treatment and reduce cardiovascular risks in patients with T2DM using GLP-1 receptor agonists (GLP-1 RAs). Upon completion of this activity, participants should be better able to: Review the role of, current guidance, and approved indications for GLP-1 RAs in the management of T2DM, Describe the difference between primary and secondary prevention of cardiovascular events and the mechanism(s) proposed for GLP-1 RAs that may reduce cardiovascular risks in patients with T2DM, Evaluate the benefits and risks of GLP-1 RAs based on results from recent clinical trials, especially in terms of primary and secondary cardiovascular prevention, Integrate GLP-1 RAs, as appropriate and using shared decision-making, into the care of patients with T2DM.
Kurt Schalper, MD, PhD - Navigating the Complexities of Biomarker Testing in the Expanding Field of Precision Immuno-Oncology: Latest Evidence, Current Challenges, and Practical Guidance for Pathologists
Go online to PeerView.com/JZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies are demonstrating remarkable clinical activity in an increasing number of malignancies, and as the immunotherapy arsenal has continued to expand, so has the importance of predictive biomarkers to guide clinical decisions and identify patients who are most likely to benefit from specific immune checkpoint inhibitors or combinations. A number of proven and putative biomarkers have been and continue to be evaluated, including PD-L1 expression, MSI/MMR, TMB, LAG-3, and others. Pathologists play an essential role in carrying out appropriate testing for these biomarkers. This onDemand activity based on a recent live PeerView Virtual Seminar and Workshop provides pathology professionals with evidence-based and practical expert instruction on biomarker testing in the era of precision cancer immunotherapy. In the Seminar segments, an expert panel reviews evidence on current and emerging immunotherapies and biomarkers, and the Workshop segments focus on the nuances of applying this evidence to pathology practice, as well as strategies for collaborating with oncology professionals to interpret biomarker testing results when making clinical decisions for patients with cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest evidence on established/emerging biomarkers (including PD-L1, MSI/MMR, and TMB, among others) and the rationale for their use to predict benefit from cancer immunotherapies, Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cutpoints, and other nuances, Apply the latest evidence and recommendations for cancer immunotherapy biomarker testing in community and academic settings, Implement effective strategies for interdisciplinary collaboration and coordination among pathologists, oncologists, and other key professionals regarding selection and interpretation of immunotherapy biomarker tests to guide clinical decision-making in immuno-oncology.
Naval Daver, MD / Joseph D. Khoury, MD, FCAP - The Pathology–Oncology Partnership in AML: Identifying and Treating the Diversity of Disease Subtypes
Go online to PeerView.com/PDK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist-oncologist panel discusses how modern, team-based treatment decisions are guided by the results of molecular/pathology testing across a wide range of acute myeloid leukemia (AML) settings, while also profiling how new evidence influences pathologic assessment and treatment selection across the continuum of AML care. Upon completion of this activity, participants should be better able to: Identify specific molecular and histopathologic features that can inform the diagnosis of different AML subtypes, including secondary AML/AML-MRC or FLT3- or IDH-mutant AML, Select appropriate evidence-based molecular/pathology tests to confirm a diagnosis of AML, Develop molecular testing strategies to collect relevant information over the course of the AML treatment continuum, Recommend appropriate, safe management options for patients with diverse AML subtypes in collaboration with the wider oncology management team.
Philip A. Thompson, MB, MS / William G. Wierda, MD, PhD - Achieving Innovation in CLL Care With BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum
Go online to PeerView.com/ZJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel of hematologist-oncologists offers guidance on best practices for integrating Bruton’s tyrosine kinase (BTK) inhibitor options into chronic lymphocytic leukemia (CLL) treatment by presenting real-world clinical scenarios designed to illustrate cutting-edge treatment selection and sequencing strategies across the spectrum of CLL care, from treatment-naïve to relapsed disease. Upon completion of this activity, participants should be better able to: Discuss the implications of mechanistic and selectivity differences among first- and second-generation BTK inhibitors in the context of CLL care, Summarize updated clinical evidence and practice guideline recommendations for the use of BTK inhibitors in treatment-naïve and relapsed CLL, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL, or in patients unable to tolerate BTK inhibitor therapy, Develop a management plan to address unique adverse events associated with the use of BTK inhibitors in patients with CLL.
Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN - Visualizing the Potential Role of HIF-PH Inhibitors in the Treatment of Anemia in Chronic Kidney Disease
Go online to PeerView.com/KMS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic kidney disease (CKD) discusses anemia in CKD and explores the potential role of HIF-PH inhibitors in the treatment of this condition. Upon completion of this activity, participants will be able to: Identify the epidemiology, pathology, and burden of anemia associated with CKD, Discuss limitations of the current model of treatment for anemia associated with CKD, Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD, Recognize the benefits and limitations of current and emerging agents to treat anemia in CKD.
Robert Z. Orlowski, MD, PhD / Sagar Lonial, MD, FACP - The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-Based Treatment From CD38 to BCMA
Go online to PeerView.com/BUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView “How I Think, How I Treat” CME video activity, multiple myeloma (MM) experts explore the era of antibody-based therapy and the implications of new science for treatment decisions from early disease settings through the management of relapsed/refractory MM. By sharing their personal insights and intra-institutional experiences, and combining these reflections with in-depth analysis of recent evidence on anti-CD38, SLAMF7, and BCMA-targeting antibodies, Drs. Sagar Lonial and Robert Z. Orlowski recommend ways to improve clinical outcomes related to the integration of antibody therapy into modern MM management. Don’t miss this opportunity to get informed on the unique anticancer mechanisms of antibody-based therapy, as well as the safety and efficacy evidence supporting its use across the wide spectrum of MM presentations. Upon completion of this activity, participants should be better able to: Summarize the therapeutic targets and mechanisms associated with novel antibodies in multiple myeloma, including CD38, SLAMF7, and BCMA, among others, Discuss current efficacy and safety evidence surrounding the use of novel and next-generation antibodies in patients with newly diagnosed or relapsed/refractory multiple myeloma, Develop personalized treatment regimens with novel antibody components for patients with newly diagnosed or relapsed/refractory multiple myeloma, Manage practical considerations related to the use of antibody-based regimens in multiple myeloma, including unique adverse events, dosing considerations, and interference with blood compatibility testing, among others.